Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Multiple myeloma (MM), which is caused by ... can insert into the cell membrane and inhibit activation of AKT1, leading to myeloma cell death 10. Perifosine might also augment the impact of ...

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat adults with newly diagnosed ...

Daratumumab significantly delays smoldering multiple myeloma progression, with a 63.1% progression-free survival rate at 5 years, reducing the risk of death by 48%. The 66th American Society of ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...

Ashraf Z. Badros, MB, ChB, discusses the results of the phase 3 AURIGA trial which evaluated daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.